[go: up one dir, main page]

RU2013127155A - Новые замещенные бициклические ароматические соединения в качестве ингибиторов s-нитрозоглутатион-редуктазы - Google Patents

Новые замещенные бициклические ароматические соединения в качестве ингибиторов s-нитрозоглутатион-редуктазы Download PDF

Info

Publication number
RU2013127155A
RU2013127155A RU2013127155/04A RU2013127155A RU2013127155A RU 2013127155 A RU2013127155 A RU 2013127155A RU 2013127155/04 A RU2013127155/04 A RU 2013127155/04A RU 2013127155 A RU2013127155 A RU 2013127155A RU 2013127155 A RU2013127155 A RU 2013127155A
Authority
RU
Russia
Prior art keywords
group
compound according
hydroxynaphthalen
compound
benzoic acid
Prior art date
Application number
RU2013127155/04A
Other languages
English (en)
Inventor
Сичэн СУНЬ
Цзянь ЦЮ
Адам СТАУТ
Original Assignee
Н30 Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Н30 Фармасьютикалс, Инк. filed Critical Н30 Фармасьютикалс, Инк.
Publication of RU2013127155A publication Critical patent/RU2013127155A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/33—Polycyclic acids
    • C07C63/337—Polycyclic acids with carboxyl groups bound to condensed ring systems
    • C07C63/34—Polycyclic acids with carboxyl groups bound to condensed ring systems containing two condensed rings
    • C07C63/36—Polycyclic acids with carboxyl groups bound to condensed ring systems containing two condensed rings containing one carboxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/17—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01284—S-(hydroxymethyl)glutathione dehydrogenase (1.1.1.284), i.e. nitroreductase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Соединение Формулы 1:Формула 1где Rвыбран из группы, состоящей из Н, F и Cl;Rи Rнезависимо выбраны из группы, состоящей из Н, F, Cl, Br, Me, ОСНи циано;Rвыбран из группы, состоящей из Н, F, Cl, Br, Me и ОСН;Х выбран из группы, состоящей из,,,,,,,,,,, и;А выбран из группы, состоящей из,,,,,,, и;Rвыбран из группы, состоящей из F, Cl, Br, СН, CF, ОСН, циано, N(СН)и морфолино;n выбран из группы, состоящей из 0, 1 и 2;Rвыбран из группы, состоящей из Н, F, Cl, Br, СН, CF, ОСН, циано, N(СН)и морфолино;при условии, что если Х является, а A является СООН, то по меньшей мере один из R, R, R, Rи Rне является водородом, или n должен быть >0, и R, будучи в мета-положении к нафталину, не может быть СН.2. Соединение по п.1, отличающееся тем, чтоХ выбран из группы, состоящей из,,, и.3. Соединение по п.1, отличающееся тем, что Х является.4. Соединение по п.3, отличающееся тем, что Rявляется водородом.5. Соединение по п.3, отличающееся тем, что Rявляется водородом.6. Соединение по п.1, отличающееся тем, что соединением является соединение Формулы 2Формула 27. Соединение по п.6, отличающееся тем, чтоRвыбран из группы, состоящей из Н и F;Rвыбран из группы, состоящей из Н, F, Cl, Br и циано;Rвыбран из группы, состоящей из Н, F и Cl;Rявляется Н; иRвыбран из группы, состоящей из Н, F, Cl и циано.8. Соединение по п.6, отличающееся тем, что Rвыбран из группы, состоящей из F и Cl.9. Соединение по п.6, отличающееся тем, что Rвыбран из группы, состоящей из F, Cl, Br, Me, ОСНи циано.10. Соединение по п.6, отличающееся тем, что Rвыбран из группы, состоящей из F, Cl, Br, Me, ОСНи циано.11. Соединение по п.6, отличающееся тем, что Rвыбран из группы, состоящей из F, Cl, Br, Me и ОСН;12. Соединение по п.6, отличающееся тем, что Rвыбран из группы, состоящей из F, Cl, Br, СН, CF, ОСН, циано, N(СН)и морфолин�

Claims (32)

1. Соединение Формулы 1:
Figure 00000001
Формула 1
где R1 выбран из группы, состоящей из Н, F и Cl;
R2a и R2b независимо выбраны из группы, состоящей из Н, F, Cl, Br, Me, ОСН3 и циано;
R2c выбран из группы, состоящей из Н, F, Cl, Br, Me и ОСН3;
Х выбран из группы, состоящей из
Figure 00000002
,
Figure 00000003
,
Figure 00000004
,
Figure 00000005
,
Figure 00000006
Figure 00000007
,
Figure 00000008
,
Figure 00000009
,
Figure 00000010
,
Figure 00000011
Figure 00000012
,
Figure 00000013
,
Figure 00000014
, и
Figure 00000015
;
А выбран из группы, состоящей из
Figure 00000016
,
Figure 00000017
,
Figure 00000018
,
Figure 00000019
,
Figure 00000020
,
Figure 00000021
,
Figure 00000022
, и
Figure 00000023
;
R3 выбран из группы, состоящей из F, Cl, Br, СН3, CF3, ОСН3, циано, N(СН3)2 и морфолино;
n выбран из группы, состоящей из 0, 1 и 2;
R4 выбран из группы, состоящей из Н, F, Cl, Br, СН3, CF3, ОСН3, циано, N(СН3)2 и морфолино;
при условии, что если Х является
Figure 00000002
, а A является СООН, то по меньшей мере один из R1, R2a, R2b, R2c и R4 не является водородом, или n должен быть >0, и R3, будучи в мета-положении к нафталину, не может быть СН3.
2. Соединение по п.1, отличающееся тем, что
Х выбран из группы, состоящей из
Figure 00000002
,
Figure 00000004
,
Figure 00000003
, и
Figure 00000005
.
3. Соединение по п.1, отличающееся тем, что Х является
Figure 00000002
.
4. Соединение по п.3, отличающееся тем, что R2c является водородом.
5. Соединение по п.3, отличающееся тем, что R2b является водородом.
6. Соединение по п.1, отличающееся тем, что соединением является соединение Формулы 2
Figure 00000024
Формула 2
7. Соединение по п.6, отличающееся тем, что
R1 выбран из группы, состоящей из Н и F;
R2a выбран из группы, состоящей из Н, F, Cl, Br и циано;
R2b выбран из группы, состоящей из Н, F и Cl;
R2c является Н; и
R4 выбран из группы, состоящей из Н, F, Cl и циано.
8. Соединение по п.6, отличающееся тем, что R1 выбран из группы, состоящей из F и Cl.
9. Соединение по п.6, отличающееся тем, что R2a выбран из группы, состоящей из F, Cl, Br, Me, ОСН3 и циано.
10. Соединение по п.6, отличающееся тем, что R2b выбран из группы, состоящей из F, Cl, Br, Me, ОСН3 и циано.
11. Соединение по п.6, отличающееся тем, что R2c выбран из группы, состоящей из F, Cl, Br, Me и ОСН3;
12. Соединение по п.6, отличающееся тем, что R4 выбран из группы, состоящей из F, Cl, Br, СН3, CF3, ОСН3, циано, N(СН3)2 и морфолино.
13. Соединение по п.1, отличающееся тем, что соединением является соединение Формулы 3
Figure 00000025
Формула 3
14. Соединение по п.13, отличающееся тем, что Х является
Figure 00000002
15. Соединение по п.14, отличающееся тем, что А является СООН.
16. Соединение по п.13, отличающееся тем, что соединением является соединение Формулы 4
Figure 00000026
Формула 4
17. Соединение по п.16, отличающееся тем, что R2c является Н.
18. Соединение по п.16, отличающееся тем, что R2b является Н.
19. Соединение по п.16, отличающееся тем, что
R1 выбран из группы, состоящей из Н и F;
R2b выбран из группы, состоящей из Н, F и Cl;
R2c является Н; и
R4 выбран из группы, состоящей из Н, F, Cl и циано.
20. Соединение по п.1, отличающееся тем, что соединением является соединение Формулы 5
Figure 00000027
Формула 5
21. Соединение по п.20, отличающееся тем, что Х является
Figure 00000002
.
22. Соединение по п.21, отличающееся тем, что А является СООН.
23. Соединение по п.20, отличающееся тем, что соединением является соединение Формулы 6
Figure 00000028
Формула 6
24. Соединение по п.23, отличающееся тем, что R2c является Н.
25. Соединение по п.23, отличающееся тем, что K2b является Н.
26. Соединение по п.23, отличающееся тем, что
R2a выбран из группы, состоящей из Н, F, Cl, Br и циано;
R2a выбран из группы, состоящей из Н, F и Cl;
R2c является H; и
R4 выбран из группы, состоящей из Н, F, Cl и циано.
27. Соединение по п.1, отличающееся тем, что соединение выбрано из группы, состоящей из
3-хлор-4-(6-гидроксинафталин-2-ил)бензойной кислоты;
3-фтор-4-(6-гидроксинафталин-2-ил)бензойной кислоты;
4-(6-гидроксинафталин-2-ил)-3-метоксибензойной кислоты;
3-(диметиламино)-4-(6-гидроксинафталин-2-ил)бензойной кислоты;
3-циано-4-(6-гидроксинафталин-2-ил)бензойной кислоты;
4-(6-гидроксинафталин-2-ил)-3-морфолинобензойной кислоты;
4-(1-бром-6-гидроксинафталин-2-ил)бензойной кислоты;
4-(6-гидрокси-1-метилнафталин-2-ил)бензойной кислоты;
4-(1-циано-6-гидроксинафталин-2-ил)бензойной кислоты;
4-(6-гидрокси-3-метоксинафталин-2-ил)бензойной кислоты;
4-(1-хлор-6-гидроксинафталин-2-ил)бензойной кислоты;
6-(4-(1Н-тетразол-5-ил)фенил)нафталин-2-ола;
5-(6-гидроксинафталин-2-ил)пиколиновой кислоты;
6-(6-гидроксинафталин-2-ил)никотиновой кислоты;
5-(6-гидроксинафталин-2-ил)пиразин-2-карбоновой кислоты;
2-(6-гидроксинафталин-2-ил)пиримидин-5-карбоновой кислоты;
6-(6-гидроксинафталин-2-ил)пиридазин-3-карбоновой кислоты;
5-(6-гидроксинафталин-2-ил)пиримидин-2-карбоновой кислоты;
6-(1H-бензо[d][1,2,3]триазол-6-ил)нафталин-2-ола;
4-(6-гидроксинафталин-2-ил)-3-(трифторметил)бензойной кислоты;
3-хлор-4-(3-фтор-6-гидроксинафталин-2-ил)бензойной кислоты;
4-(3-хлор-6-гидроксинафталин-2-ил)бензойной кислоты;
4-(3-фтор-6-гидроксинафталин-2-ил)бензойной кислоты;
4-(6-гидрокси-1-метоксинафталин-2-ил)бензойной кислоты;
4-(1-фтор-6-гидроксинафталин-2-ил)бензойной кислоты;
4-(6-гидрокси-3-метилнафталин-2-ил)бензойной кислоты;
4-(1-циано-5-фтор-6-гидроксинафталин-2-ил)бензойной кислоты;
4-(1-циано-6-гидроксинафталин-2-ил)-3-фторбензойной кислоты;
3-хлор-4-(5-фтор-6-гидроксинафталин-2-ил)бензойной кислоты;
4-(5-фтор-6-гидроксинафталин-2-ил)бензойной кислоты;
3-фтор-4-(5-фтор-6-гидроксинафталин-2-ил)бензойной кислоты; и
4-(5-фтор-6-гидроксинафталин-2-ил)-3-метилбензойной кислоты.
28. Применение соединения Формулы 1 по п.1 или его фармацевтически приемлемой соли в качестве ингибитора GSNOR.
29. Применение соединения по п.27 или его фармацевтически приемлемой соли в качестве ингибитора GSNOR.
30. Фармацевтическая композиция, включающая терапевтически эффективное количество соединения по п.1 вместе с фармацевтически приемлемым носителем или формообразующим средством.
31. Способ лечения заболевания или состояния, который включает введение терапевтически эффективного количества соединения Формулы 1 по п.1 пациенту, нуждающемуся в этом.
32. Способ получения соединения Формулы 1 по п.1.
RU2013127155/04A 2010-12-16 2011-12-16 Новые замещенные бициклические ароматические соединения в качестве ингибиторов s-нитрозоглутатион-редуктазы RU2013127155A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42379910P 2010-12-16 2010-12-16
US61/423,799 2010-12-16
PCT/US2011/065502 WO2012083171A1 (en) 2010-12-16 2011-12-16 Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors

Publications (1)

Publication Number Publication Date
RU2013127155A true RU2013127155A (ru) 2015-01-27

Family

ID=46245126

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013127155/04A RU2013127155A (ru) 2010-12-16 2011-12-16 Новые замещенные бициклические ароматические соединения в качестве ингибиторов s-нитрозоглутатион-редуктазы

Country Status (11)

Country Link
US (7) US9249132B2 (ru)
EP (2) EP2651223A4 (ru)
JP (2) JP5990187B2 (ru)
KR (1) KR20130138292A (ru)
CN (1) CN103328430A (ru)
AU (1) AU2011343518B2 (ru)
BR (1) BR112013014681A2 (ru)
CA (1) CA2821412A1 (ru)
IL (1) IL226834A (ru)
RU (1) RU2013127155A (ru)
WO (2) WO2012083171A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811791C (en) * 2010-10-08 2020-06-23 N30 Pharmaceuticals, Inc. Substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
EP2651223A4 (en) 2010-12-16 2015-07-22 Nivalis Therapeutics Inc NOVEL BICYCLIC AROMATIC COMPOUNDS SUBSTITUTED AS INHIBITORS OF S-NITROSOGLUTATHION REDUCTASE
US20140094465A1 (en) * 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors
WO2016128905A1 (en) * 2015-02-10 2016-08-18 Glenmark Pharmaceuticals S.A. Thienopyrrole compounds as s-nitrosoglutathione reductase inhibitors
US10399946B2 (en) 2015-09-10 2019-09-03 Laurel Therapeutics Ltd. Solid forms of an S-Nitrosoglutathione reductase inhibitor
WO2017151725A1 (en) * 2016-03-03 2017-09-08 Nivalis Therapeutics, Inc. Formulations of an s-nitrosoglutathione reductase inhibitor
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
CN109999029B (zh) * 2019-03-07 2020-03-31 南京医科大学 N6022在治疗糖尿病外周动脉疾病中的医药用途
US20230121865A1 (en) * 2020-03-04 2023-04-20 National University Corporation Tokai National Higher Education And Research System Method for producing naphthylsilole, naphthylsilole containing heterocyclic group, and graphene nanoribbon containing heterocyclic group
CN112574193B (zh) * 2020-12-31 2022-05-17 南京医科大学 一类口服gsnor抑制剂及其药物用途
CN115417913B (zh) * 2022-08-26 2024-10-29 天津医科大学 靶向雌激素受体的谷胱甘肽响应protac降解剂的制备方法及应用
WO2024104452A1 (zh) 2022-11-17 2024-05-23 长春金赛药业有限责任公司 Mc4r拮抗剂化合物、药物组合物及其在医药上的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
LU86022A1 (fr) 1985-07-25 1987-02-04 Cird Derives aromatiques polycyliques,leur procede de preparation et leur application dans les domaines pharmaceutique et cosmetique
FR2676052B1 (fr) 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK77393D0 (da) 1993-06-29 1993-06-29 Novo Nordisk As Aktivering af enzymer
DE19522167B4 (de) 1994-06-20 2007-05-10 Merck Patent Gmbh 1,2-Difluornaphthalin-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19522195A1 (de) 1994-06-20 1995-12-21 Hoechst Ag Trifluornaphthalin-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
DE4427199A1 (de) 1994-08-01 1996-02-08 Hoechst Ag 3,4-Difluorpyridine und ihre Verwendung in flüssigkristallinen Mischungen
DE19517060A1 (de) 1995-05-10 1996-11-14 Hoechst Ag 1-Fluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517038A1 (de) 1995-05-10 1996-11-14 Hoechst Ag 1,8-Difluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen
KR19990029052A (ko) 1995-07-17 1999-04-15 악커만 요아힘, 되르 클라우스 강유전성 액정 혼합물
PL330814A1 (en) 1996-06-20 1999-06-07 Regents Board Of Compounds for and methods of delivering pharmaceutical preparations and their application
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
IL133008A0 (en) 1997-05-28 2001-03-19 Aventis Pharm Prod Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
WO2000031045A1 (fr) * 1998-11-20 2000-06-02 Torii Pharmaceutical Co., Ltd. Derives de naphtalene
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ATE503743T1 (de) 2000-04-27 2011-04-15 Astellas Pharma Inc Kondensierte heteroarylderivate
AU2001296502B2 (en) 2000-10-02 2005-06-09 Molecular Probes, Inc. Reagents for labeling biomolecules having aldehyde or ketone moieties
US6359182B1 (en) 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
US7049308B2 (en) 2000-10-26 2006-05-23 Duke University C-nitroso compounds and use thereof
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
JP2002226464A (ja) 2001-01-30 2002-08-14 Sumitomo Pharmaceut Co Ltd トリアリール類縁体およびその利用
US7173128B2 (en) 2001-08-13 2007-02-06 Ciba Specialty Chemicals Corporation Ultraviolet light absorbers
AT500490A1 (de) 2001-10-16 2006-01-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von substituierten thiazolinen und deren zwischenprodukte
AU2003265493A1 (en) 2002-08-19 2004-03-03 Rensselaer Polytechnic Institute Liquid crystal polymers
AU2003261834A1 (en) 2002-08-30 2004-05-04 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
US7118730B2 (en) 2002-12-16 2006-10-10 Bf Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
WO2004080170A2 (en) 2003-03-10 2004-09-23 Basf Aktiengesellschaft Amino substituted benzo(hetero)cyclic derivatives
CL2004000985A1 (es) 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
MXPA05013054A (es) 2003-06-04 2006-08-23 Univ Duke Composiciones y metodos para modular s-nitrosoglutationa reductasa.
AU2003304416A1 (en) 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
US7638519B2 (en) 2003-12-23 2009-12-29 Myogen, Inc. Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
ITTO20040125A1 (it) 2004-03-01 2004-06-01 Rotta Research Lab Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
WO2006004722A2 (en) 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
WO2006023821A2 (en) 2004-08-20 2006-03-02 The Trustees Of Columbia University In The City Of New York Ligands for aldoketoreductases
WO2006034512A2 (en) 2004-09-23 2006-03-30 Bayer Pharmaceuticals Corporation Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
AU2005311951A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Quinoline tachykinin receptor antagonists
EP1683523A1 (en) 2005-01-25 2006-07-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. 2-Phenylquinoxalines as inhibitors for MPP1
WO2006127329A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Quinoline derivatives useful as modulators of ion channels
EP3312292B1 (en) 2005-05-31 2019-09-25 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
WO2007005668A2 (en) 2005-06-30 2007-01-11 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
EP1940402A4 (en) * 2005-09-20 2009-06-03 Merck & Co Inc AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
AU2007271187A1 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine H4 receptor
GB0618168D0 (en) 2006-09-15 2006-10-25 Babraham Inst Compounds
KR101299233B1 (ko) 2006-10-31 2013-08-22 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
CA2707449A1 (en) 2006-12-01 2009-06-12 President And Fellows Of Harvard College Compounds and methods for enzyme-mediated tumor imaging and therapy
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
DE102007015169A1 (de) * 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
BRPI0701664A2 (pt) 2007-05-28 2009-01-13 Fundacao Universidade Fed De Sco Carlos 4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
EA200901662A1 (ru) 2007-07-02 2010-06-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Агонисты фарнезоидного х-рецептора
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
EP2229451A4 (en) 2007-12-13 2012-06-13 Univ Indiana Res & Tech Corp MATERIALS AND METHOD FOR INHIBITING ANIMALS S NITROSOGLUTATHION REDUCTASE
US20100144733A1 (en) 2008-04-28 2010-06-10 Institute For Oneworld Health Compounds, compositions and methods comprising heteroaromatic derivatives
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
CN102186478B (zh) * 2008-08-15 2013-10-02 N30医药品公司 作为治疗剂的s-亚硝基谷胱甘肽还原酶的新型吡咯抑制剂
WO2010019909A1 (en) * 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Pyrrole inhibitors of s-nitrosoglutathione reductase
US8470857B2 (en) * 2008-08-15 2013-06-25 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
KR101648377B1 (ko) 2008-10-15 2016-08-16 깃세이 야쿠힌 고교 가부시키가이샤 축합환 유도체 및 그 의약용도
EA018891B1 (ru) 2008-10-23 2013-11-29 Вертекс Фармасьютикалз, Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
WO2010080414A2 (en) 2008-12-19 2010-07-15 The University Of North Carolina At Chapel Hill Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents
WO2010107476A1 (en) 2009-03-19 2010-09-23 Duke University Inhibiting gsnor
RU2585763C2 (ru) 2010-02-12 2016-06-10 Нивалис Терапьютикс,Инк. Новые ингибиторы s-нитрозоглутатионредуктазы
WO2012009227A1 (en) 2010-07-16 2012-01-19 N30 Pharmaceuticals, Llc Novel dihydropyridin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists
CA2811791C (en) * 2010-10-08 2020-06-23 N30 Pharmaceuticals, Inc. Substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
EP2651223A4 (en) 2010-12-16 2015-07-22 Nivalis Therapeutics Inc NOVEL BICYCLIC AROMATIC COMPOUNDS SUBSTITUTED AS INHIBITORS OF S-NITROSOGLUTATHION REDUCTASE
US20140094465A1 (en) 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors

Also Published As

Publication number Publication date
US20160279117A1 (en) 2016-09-29
US20140329821A1 (en) 2014-11-06
AU2011343518A1 (en) 2013-07-04
US9364481B2 (en) 2016-06-14
US20150183774A1 (en) 2015-07-02
BR112013014681A2 (pt) 2016-10-04
EP2651871A4 (en) 2015-07-22
US9012646B2 (en) 2015-04-21
EP2651223A1 (en) 2013-10-23
US9249132B2 (en) 2016-02-02
WO2012083171A1 (en) 2012-06-21
JP5898230B2 (ja) 2016-04-06
US9221810B2 (en) 2015-12-29
CA2821412A1 (en) 2012-06-21
KR20130138292A (ko) 2013-12-18
EP2651223A4 (en) 2015-07-22
US20130261122A1 (en) 2013-10-03
WO2012083165A1 (en) 2012-06-21
CN103328430A (zh) 2013-09-25
EP2651871A1 (en) 2013-10-23
US20130261123A1 (en) 2013-10-03
JP2014506875A (ja) 2014-03-20
US20160108011A1 (en) 2016-04-21
JP5990187B2 (ja) 2016-09-07
IL226834A (en) 2016-09-29
AU2011343518B2 (en) 2016-11-10
US8785643B2 (en) 2014-07-22
JP2013545821A (ja) 2013-12-26
US20160067254A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
RU2013127155A (ru) Новые замещенные бициклические ароматические соединения в качестве ингибиторов s-нитрозоглутатион-редуктазы
RU2013112122A (ru) Новые замещенные хинолиновые соединения как ингибиторы s-нитрозоглутатион-редуктазы
RU2486181C2 (ru) Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
RU2500673C2 (ru) Гетероциклические ингибиторы мек и способы их применения
RU2007132262A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2020526561A5 (ru)
RU2439068C2 (ru) Модуляторы mglur5
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
RU2013141528A (ru) ИНГИБИТОРЫ РЕЦЕПТОРОВ RORгаммаТ
CA2697077A1 (en) 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
IL276946B (en) Antiproliferative compounds and methods of use thereof
RU2006107653A (ru) Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли
JP2013513613A5 (ru)
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2008513515A5 (ru)
NZ590268A (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
HRP20161177T1 (hr) Modulator glukagonskog receptora
JP2011504497A5 (ru)
JP2016505619A5 (ru)
JP2010532386A5 (ru)
RU2009133259A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2004508357A5 (ru)
NZ590784A (en) Pyrazolopyridine kinase inhibitors
NZ612544A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
CA2561628A1 (en) Histamine h3 receptor agents, preparation and therapeutic uses

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20170811